UNASSIGNED: The molecular regulation of muscle function in @entity626 is unclear. Elevated @entity2057 regulation marker expression was associated with reduced muscle strength in @entity626 . The level of protein expression appears to be different between muscle, knee joint and serum, suggesting that @entity32 is regulated differently within these tissues. INTRODUCTION: @entity121 is common in @entity626 ( @entity571 ). Numerous biochemical molecules have been implicated in the development of @entity571 ; however, these have only been identified in the joint and serum. We compared the expression of @entity8252 ( @entity8252 ) and @entity4012 ( @entity4012 ) in muscle of @entity1 with knee @entity571 and asymptomatic individuals and examined whether @entity8252 was also present in the joint and serum. METHODS: Muscle and blood samples were collected from 19 @entity1 with knee @entity571 and 10 age-matched asymptomatic individuals. Synovial fluid and muscle biopsies were collected from the @entity571 group during knee replacement surgery. @entity8252 and @entity4012 were measured in the skeletal muscle. @entity8252 abundance was also analysed in the serum of both groups and synovial fluid from the @entity571 group. Knee extensor strength was measured and correlated with @entity8252 and @entity4012 in the muscle. RESULTS: @entity4012 protein expression was higher (p   =   0.04), whereas @entity8252 expression was lower (p   =   0.02) in the muscle of the @entity571 group. Strength was also lower in the @entity571 group and was inversely correlated with @entity4012 expression. No correlation was found between @entity8252 in the joint, muscle or serum. CONCLUSION: Skeletal muscle, particularly the @entity121 , is affected in @entity1 with knee @entity571 where elevated @entity4012 protein expression was associated with reduced muscle strength. While @entity8252 protein expression in the muscle was lower in the knee @entity571 group, no correlation was found between the expression of @entity8252 protein in the muscle, joint and serum, which suggests that @entity32 is regulated differently within these tissues. Australian Clinical Trials Registry (ACTR) number: ACTRN12613000467730 ( http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000467730_isBasic=True ).

The level of @entity4012 and @entity8252 in skeletal muscle, serum and synovial fluid in @entity1 with XXXX : a case control study.

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis'] @entity571 :: ('MESH:D010003', 'Disease') :: ['OA'] @entity4012 :: ('2308', 'Gene') :: ['Forkhead box protein-O1', 'FoxO1'] @entity8252 :: ('3600', 'Gene') :: ['interleukin-15', 'IL-15'] @entity2057 :: ('MESH:D009133', 'Disease') :: ['muscle atrophy'] @entity121 :: ('MESH:D009135', 'Disease') :: ['Impaired muscle function', 'quadriceps']
@entity626 :: (MESH:D020370,Disease) :: ['knee osteoarthritis']
